OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA) – Yahoo Finance
FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1– Antripsyn Deficiency (Alpha-1) in U.S. Adult Population
BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx saliva collection device for OTC (i.e. direct-to-consumer) use. The device had been previously cleared for prescription use by the FDA. ORAcollect®•Dx joins the Oragene®•Dx product line which previously received FDA general clearance for prescription and OTC use. This new designation now allows ORAcollect®•Dx devices to be used by OraSure’s commercial partners and legally marketed with their therapeutics or devices in conjunction with their product’s intended use. Both the ORAcollect®•Dx, and Oragene®•Dx devices are designed to be used by an adult at home, without direction from a healthcare professional.
OraSure received this designation through its partnership with Grifols to support screening for alpha1-antitrypsin deficiency (alpha-1) in individuals who may be at risk for alpha-1. Alpha-1 raises patients’ risks for lung disorders and it is estimated that about 3% of COPD patients have alpha-1. Beginning in Q2 2023, Grifols will offer free AlphaID™ At Home Genetic Health Risk Service, supporting alpha-1 screening, that utilize the ORAcollect®•Dx device to help identify individuals at risk. According to the Centers for Disease Control, COPD affects over 15 million people in the United States.
“This clearance represents a major milestone for OraSure as we work in conjunction with our commercial partners to increase access to healthcare,” said Kathleen Weber, President of Molecular Solutions for OraSure Technologies. “With the movement toward precision medicine, we increasingly see the need for genetic testing supporting FDA approved therapeutics as drugs become more specialized for targeted patient populations. This expanded designation now allows us to better support our customers and expands the potential for future indications with the ORAcollect®•Dx device.”
“We look forward to working with an experienced partner such as OraSure to expand access to alpha-1 testing and awareness,” said Antonio Martínez, President, Grifols Diagnostic.
About DNA Genotek
DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., focuses on providing high-quality biological sample collection products and end-to-end services for human genomics and microbiome applications. The Company’s Oragene®•Dx and ORAcollect®•Dx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro diagnostic use. DNA Genotek also offers Research Use Only products to collect and preserve large amounts of DNA or RNA from multiple sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Important Information
This press release contains certain forward-looking statements, including with respect to the Company’s products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: risk that the Company’s exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect operating results, business or investor perceptions; the diversion of management’s attention from the Company’s ongoing business and regular business responsibilities due to the Company’s exploration of strategic alternatives; ability to resolve the Company’s ongoing manufacturing challenges and satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company’s business and ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Investor Contact:
Media Contact:
Scott Gleason
Amy Koch
SVP Investor Relations & Corporate Communications
Sr. Mgr. Corporate Communications
484-425-0588
484-523-1815
sgleason@orasure.com
media@orasure.com
Related Quotes
More hikes are likely coming. Can your portfolio handle it?
(Bloomberg) — After nearly two years of disappointment and $6 trillion of losses, speculation that the bottom in Chinese stocks has finally arrived is stoking a world-beating rally this week.Most Read from BloombergMusk Plans to Eliminate Half of Twitter Jobs to Cut CostsMusk Eliminates ‘Days of Rest’ From Twitter Employee CalendarsBlackstone’s $70 Billion Real Estate Fund for Retail Investors Is Losing SteamLottery Winner Keeps $30 Million Jackpot Secret From Wife and ChildHow a Mysterious Chi
When Lumen Technologies (NYSE: LUMN) closed its two asset sales and appointed a new CEO over the past couple of months, it seemed highly probable that the company would cut its dividend. Is this a sign of Lumen's impending demise, or can the business be turned around? With a new CEO and a better balance sheet thanks to recent asset sales, Lumen could be an interesting stock for deep-value investors, as dividend seekers sell off their shares.
Bloom Energy (BE) delivered earnings and revenue surprises of -233.33% and 5.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
This is the second time I get to write about safe stocks to buy and hold. I liked the list I put together in October (and have positions in a couple), but I’m happy to have a second bite at the apple and give this list a revision. That’s because there are more than seven safe stocks, and more than one way to think about them. One tried-and-true method is to look for best-in-class stocks. Long-term investments should consider buying the best and forgetting the rest. Sure there’s a place for a spe
Thursday was an eventful day for drug maker Teva Pharmaceutical Industries (NYSE: TEVA). Not only did the company release its latest set of quarterly earnings, it also reached a settlement in a major lawsuit. Arguably, the more important development is the legal settlement, in which Teva has agreed to pay a total of $523 million to the state of New York.
As investor days go, Boeing (NYSE: BA) apparently had a good one. Boeing didn't have a lot of momentum coming into this week's investor day presentations. Boeing shares are down more than 40% over the past five years, weighed down first by issues involving the 737 MAX and more recently the pandemic and its impact on travel.
The president of macroeconomic research firm Lamoureux & Co., Yves Lamoureux, sees up years in the medium to long-term for stocks, even if Powell threw a "short-term wrench in the engine."
Stocks fell further on Thursday, with investors weighing their longer-term views on what the Federal Reserve's course of future policy actions could mean for the economy and their investments. The Dow Jones Industrial Average (DJINDICES: ^DJI) held up better than the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC), but all three were lower at the closing bell.
Undervalued large-cap stocks present a particular opportunity here. Markets are rebounding from their September doldrums, but all three major indices in the U.S. remain down significantly on the year with both the S&P 500 and Nasdaq in a bear market. The latest data out of the U.S. showed that inflation rose 8.2% in September from a year ago, its highest level in 40 years and still well above the U.S. Federal Reserve’s 2% target. This raises the likelihood that the central bank will continue rai
The global economy is on the path to hyperinflation and risks societal collapse if soaring prices are not brought under control, one of the world’s biggest hedge funds has warned.
Nio (NYSE: NIO) shares dipped nearly 5% Thursday morning before reversing those losses. Nio reported its October delivery data on Tuesday and investors have been digesting that information over the last two days. While Nio reported a sharp year-over-year increase in vehicle deliveries last month, it was down from September, and investors are getting more anxious about impacts from continued COVID-19 restrictions in the region.
Investors looking at the electric vehicle space certainly have several options to choose from. In this market, many valuations across EV players have come down to more attractive levels. However, choosing the best EV stocks to buy is more challenging than it looks. That’s mainly because the macro picture right now isn’t great. Due to rapidly rising interest rates, growth stocks (such as those in the EV space) have been hit very hard by Mr. Market. Indeed, the share prices of many of the companie
(Bloomberg) — Petrobras announced another blockbuster dividend payment, rewarding shareholders at a moment of growing concern that Luiz Inacio Lula da Silva’s return to power in Brazil will bring the bonanza to a halt.Most Read from BloombergMusk Plans to Eliminate Half of Twitter Jobs to Cut CostsMusk Eliminates ‘Days of Rest’ From Twitter Employee CalendarsBlackstone’s $70 Billion Real Estate Fund for Retail Investors Is Losing SteamLottery Winner Keeps $30 Million Jackpot Secret From Wife an
Shares of Axsome Therapeutics (NASDAQ: AXSM) were soaring 12.7% higher as of 11:19 a.m. ET on Thursday. Perhaps the most likely explanation for Axsome jumping today is that large institutional investors could be buying the biotech stock. Another possibility is that some short-sellers are covering their positions, creating upward pressure on the share prices in the process.
Shares of insurance company Lincoln National (NYSE: LNC) are down 32.5% as of 12:59 p.m. ET in response to what can only be considered a disastrous third-quarter report. For the three-month stretch ending in September, Lincoln National turned $4.6 billion worth of revenue into a loss of nearly $2.6 billion, or a loss of $15.17 per share. The insurer's quarterly results also reflect "unfavorable notable items" totaling $2 billion worth of charges — an adverse impact of $11.62 — linked to a yearly review of its deferred acquisition costs and subsequent changes to its reserve assumptions.
Coinbase Global (COIN) reported third-quarter earnings Thursday showing the company missed estimates on revenue and earnings. However, it retained users and lowered expenses better than analysts predicted.
Fidelity (FIS) is likely to execute share buybacks of around $500 million in the fourth quarter.
Yahoo Finance's top trending stocks in extended trading Thursday, November 3, 2022.
Investment management company First Pacific Advisors recently released its “FPA Crescent Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the quarter, the fund returned -4.71% compared to a -4.88% return for the S&P 500 Index. In the trailing twelve months, the fund declined 14.68%. However, in the third quarter, the […]